Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + liposomal doxorubicin
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Temsirolimus + liposomal doxorubicin is a combination therapy investigated primarily for the treatment of recurrent and refractory bone and soft tissue sarcomas. Temsirolimus is an intravenous inhibitor of the mechanistic target of rapamycin (mTOR), rapidly converted in vivo to sirolimus, which inhibits cell growth, proliferation, and survival by blocking mTOR signaling pathways. Liposomal doxorubicin is a formulation of the anthracycline chemotherapy agent doxorubicin encapsulated in pegylated liposomes, enhancing tumor localization and reducing toxicity compared to conventional formulations. Doxorubicin acts mainly by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis in cancer cells. The combination aims to sensitize resistant cancer stem cell populations (notably ALDH high sarcoma cells) to chemotherapy while maintaining tolerability for heavily pretreated patients[1][2][6][8].
- Brand names
- Torisel + DoxilTorisel + Caelyx
- Other names
- pegylated liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on temsirolimus + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + liposomal doxorubicin.